/Companies

Vaximm

1 known investors

Find your way into Vaximm

222 people in our graph can introduce you to the Vaximm team.

Sign up to see every warm intro you have to Vaximm

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Vaximm team. We find them
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes you can't see from your own inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

VAXIMM is a clinical-stage biopharmaceutical company developing oral T-cell immunotherapies for cancer, based on technology invented at UC San Diego. Its lead candidate VXM01 has been evaluated in clinical trials for indications such as pancreatic cancer, and the company operates as a subsidiary of OSR Health.

Founders & leadership

ANAndreas Niethammer
Andreas NiethammerFounder & Chief Executive OfficerAndreas Niethammer is the founder and chief medical officer of Vaximm, an oral immunotherapy company for cancer, and previously served as chief medical officer at Aardvark Therapeutics in San Diego, where he oversaw translational medicine and clinical development from inception through a public offering. He brings extensive clinical development experience across oncology, immunotherapy, and metabolic disorders, with expertise spanning chemotherapy, immunotherapy, radiation therapy, and investigational modalities including CAR T-cell and CAR-NK cell therapies.

Investors · 1

Frequently asked questions

What does Vaximm do?
VAXIMM is a clinical-stage biopharmaceutical company developing oral T-cell immunotherapies for cancer, based on technology invented at UC San Diego. Its lead candidate VXM01 has been evaluated in clinical trials for indications such as pancreatic cancer, and the company operates as a subsidiary of OSR Health.
Who founded Vaximm?
Vaximm was founded by Andreas Niethammer.
Who are Vaximm's investors?
Vaximm's investors include Sunstone Capital.